ess Invasive Monitoring of Resistance Mutations in Patients with ALK Rearranged Lung Cancer
Not Applicable
- Conditions
- ALK rearranged NSCLC
- Registration Number
- JPRN-UMIN000032676
- Lead Sponsor
- Asahikawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
patients who have more than one type of carcinoma patients who reject to sign the informed consent from
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine duration between clinical PD and emergence of ALK resistant mutations
- Secondary Outcome Measures
Name Time Method Concordance of ALK resistant mutations between tissue and plasma using ddPCR Concordance of ALK resistant mutations between plasma detected by ddPCR and re-biopsy tissue detected by NGS based assay at disease progression